ALDX vs. CDT, QURE, OVID, VNDA, HOWL, ACIU, GTHX, ABEO, SBTX, and GALT
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Conduit Pharmaceuticals (CDT), uniQure (QURE), Ovid Therapeutics (OVID), Vanda Pharmaceuticals (VNDA), Werewolf Therapeutics (HOWL), AC Immune (ACIU), G1 Therapeutics (GTHX), Abeona Therapeutics (ABEO), Silverback Therapeutics (SBTX), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical preparations" industry.
Aldeyra Therapeutics (NASDAQ:ALDX) and Conduit Pharmaceuticals (NASDAQ:CDT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.
59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. 7.3% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 23.5% of Conduit Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Aldeyra Therapeutics had 2 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 3 mentions for Aldeyra Therapeutics and 1 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 1.91 beat Aldeyra Therapeutics' score of 0.65 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media.
Aldeyra Therapeutics has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500.
Aldeyra Therapeutics' return on equity of -29.45% beat Conduit Pharmaceuticals' return on equity.
Aldeyra Therapeutics presently has a consensus target price of $9.33, suggesting a potential upside of 134.51%. Given Aldeyra Therapeutics' higher probable upside, equities research analysts clearly believe Aldeyra Therapeutics is more favorable than Conduit Pharmaceuticals.
Aldeyra Therapeutics received 478 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users.
Summary
Aldeyra Therapeutics beats Conduit Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
